Dr. Jo Viney, Vice President, Immunology Research at Biogen
Dr. Jo Viney is Vice President, Immunology Research at Biogen in Cambridge, MA. In this role, Jo is responsible for setting scientific research direction and strategy with a focus on target identification and validation for drug discovery and development for treating patients with autoimmune and inflammatory diseases. Jo received her PhD from St Bartholomew’s Hospital, University of London in 1991 and pursued postdoctoral fellowships first at the Imperial cancer Research Fund in London, UK, and at Genentech in the Bay Area, California. Following her training, Jo joined Immunex in 1995 and remained at the company, which was acquired by Amgen in 2002, until leaving to join Biogen Idec. Jo has advanced a portfolio of novel biologic and small molecule programs, seven of which have progressed to IND and into clinical development, for diseases such rheumatoid arthritis, asthma, atopic dermatitis, psoriasis, inflammatory bowel disease and lupus. Jo has maintained longstanding membership with the American Society of Immunologists (AAI), the British Society for Immunology (BSI) and the Society for Mucosal Immunology (SMI). She served as President of SMI from 2011-2013. Together with her SMI colleagues, she launched the journal Mucosal Immunology with Nature Publishing Group in 2007. Jo has been a member of the Scientific Advisory Board for Keystone Symposia since 2008, and she partners with KS on a number of programs for under-represented scientists. She is also member of the Scientific Advisory Board for the BioAster Technology Research Institute (IRT) in France, and for Vaxart Inc in the Bay Area.
LINKS
Experience
Staff Scientist, Autoimmunity and Inflammation Research
Immunex
Education
.
Jo Viney
Vice President, Postdoc Mentor
Immunology
My particular area of interest revolves around understanding the
mechanistic basis of immune homeostasis in organs susceptible to
inflammatory disease. Past work has included investigating tolerogenic
antigen presentation in the intestine, developing new mouse models of
colitis and studying the function of novel butyrophilin-like (BTNL)
inhibitory molecules.
I am the vice president of the immunology research group at Biogen. The group’s mission is to develop treatments for underserved immune-mediated inflammatory diseases associated with autoimmunity and fibrosis. Research extends from basic target identification and validation through to drug discovery and preclinical development.
I am the vice president of the immunology research group at Biogen. The group’s mission is to develop treatments for underserved immune-mediated inflammatory diseases associated with autoimmunity and fibrosis. Research extends from basic target identification and validation through to drug discovery and preclinical development.
Education
- Postdoc, Genentech, UK and USA, 1995
- Postdoc, Imperial Cancer Research Fund, UK, 1994
- Ph.D., St Bart’s Hospital, University of London, London, UK, 1991
- B.Sc., University of East London, London, UK, 1987
Selected Publications
- Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells.
J Immunol. 2013 Mar 1;190(5):2027-35. doi: 10.4049/jimmunol.1201760. Epub 2013 Jan 28.
Swanson RM, Gavin MA, Escobar SS, Rottman JB, Lipsky BP, Dube S, Li L, Bigler J, Wolfson M, Arnett HA, Viney JL.
PMID: 23359506 - The tale of TL1A in inflammation.
Mucosal Immunol. 2011 Jul;4(4):368-70. doi: 10.1038/mi.2011.20. Epub 2011 May 4. Review.
Hsu H, Viney JL.
PMID: 21544073 - Gatekeepers of intestinal inflammation.
Inflamm Res. 2010 Jan;59(1):1-14. Review.
Arnett HA, Viney JL.
PMID: 20066780 - Recent developments in IBD and the B7 family of costimulatory molecules.
Curr Opin Investig Drugs. 2009 May;10(5):443-51. Review.
Arnett HA, Viney JL.
PMID: 19431077 - Regulation of costimulation in the era of butyrophilins.
Cytokine. 2009 Jun;46(3):370-5. doi: 10.1016/j.cyto.2009.03.009. Epub 2009 Apr 19. Review.
Arnett HA, Escobar SS, Viney JL.
PMID: 19380239 - BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.
J Immunol. 2007 Feb 1;178(3):1523-33.
Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL.
PMID: 17237401 - From
model to mechanism: lessons of mice and men in the discovery of protein
biologicals for the treatment of inflammatory bowel disease.
Expert Opin Drug Discov. 2006 Jun;1(1):69-83. doi: 10.1517/17460441.1.1.69.
Bilsborough J, Viney JL.
PMID: 23506033 - Mouse models of inflammatory bowel disease.
Curr Opin Drug Discov Devel. 2006 Mar;9(2):207-17. Review.
Byrne FR, Viney JL.
PMID: 16566291 - Dual
infection with Helicobacter bilis and Helicobacter hepaticus in
p-glycoprotein-deficient mdr1a-/- mice results in colitis that
progresses to dysplasia.
Am J Pathol. 2005 Jun;166(6):1793-806.
Maggio-Price L, Bielefeldt-Ohmann H, Treuting P, Iritani BM, Zeng W, Nicks A, Tsang M, Shows D, Morrissey P, Viney JL.
PMID: 15920164 - The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease.
Immunol Res. 2005;31(2):151-9. Review.
Wilk JN, Bilsborough J, Viney JL.
PMID: 15778512 - Out, out darn toxin: the role of MDR in intestinal homeostasis.
Gastroenterology. 2004 Jul;127(1):339-40. Review. No abstract available.
Bilsborough J, Viney JL.
PMID: 15236205 - Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease.
Gastroenterology. 2004 Jul;127(1):300-9. Review.
Bilsborough J, Viney JL.
PMID: 15236195 - Mucosal
CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and
support function of T cells with regulatory properties.
Immunology. 2003 Apr;108(4):481-92.
Bilsborough J, George TC, Norment A, Viney JL.
PMID: 12667210 - GM-CSF treatment for Crohn's disease: a stimulating new therapy?
Curr Opin Investig Drugs. 2002 Sep;3(9):1291-6. Review.
Wilk JN, Viney JL.
PMID: 12498002 - Regulation
of mucosal dendritic cell function by receptor activator of NF-kappa B
(RANK)/RANK ligand interactions: impact on tolerance induction.
J Immunol. 2002 Oct 1;169(7):3606-12.
Williamson E, Bilsborough JM, Viney JL.
PMID: 12244151 - Getting to the guts of immune regulation.
Immunology. 2002 Jun;106(2):139-43. Review. No abstract available.
Bilsborough J, Viney JL.
PMID: 12047743 - Interleukin
18 is a primary mediator of the inflammation associated with dextran
sulphate sodium induced colitis: blocking interleukin 18 attenuates
intestinal damage.
Gut. 2002 Jun;50(6):812-20.
Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM, Viney JL.
PMID: 12010883 - Helicobacter
bilis infection accelerates and H. hepaticus infection delays the
development of colitis in multiple drug resistance-deficient (mdr1a-/-)
mice.
Am J Pathol. 2002 Feb;160(2):739-51.
Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P, Viney JL.
PMID: 11839595 - Immune fate decided by dendritic cell provocateurs.
Trends Immunol. 2001 Jan;22(1):8-10. No abstract available.
Viney JL.
PMID: 11334031 - The ins and outs of body surface immunology.
Science. 2000 Oct 6;290(5489):97-100. Review.
Hayday A, Viney JL.
PMID: 11021807
////////////
No comments:
Post a Comment